Table 2 Lesion characteristics and brain atrophy measures of all RRMS patients according to CSF-OCB status.

From: Advanced MRI features in relapsing multiple sclerosis patients with and without CSF oligoclonal IgG bands

 

ALL (n = 75)

OCB-negative (n = 29)

OCB-positive (n = 46)

Adjusted p-value

Lesion characteristics

Distribution, n (%)

 Periventricular lesions

72 (96.0%)

27 (93.1%)

45 (97.8%)

0.570a

 Corpus callosal lesions

53 (70.7%)

20 (69.0%)

33 (71.7%)

0.606a

 Juxtacortical lesions

45 (60.0%)

15 (51.7%)

30 (65.2%)

0.471a

 Brainstem lesions

21 (28.0%)

7 (24.1%)

14 (30.4%)

0.536a

 Cerebellar lesions

12 (16.0%)

1 (3.4%)

11 (23.9%)

0.057a

 Temporal lobe lesions

54 (72.0%)

19 (65.5%)

35 (76.1%)

0.299a

 Spinal cord lesions

30 (42.3%)

12 (42.9%)

18 (41.9%)

0.592a

Total volume, mL, adjusted mean (SD)

11.38 (11.89)

10.48 (11.07)

11.95 (12.46)

0.737b

Normalized brain volumes, mL, adjusted mean (SD)

White matter

742.26 (372.78)

744.52 (343.02)

740.83 (389.10)

0.669b

Gray matter

679.53 (462.51)

684.62 (568.69)

676.32 (379.80)

0.459b

Peripheral gray matter

583.04 (323.71)

584.16 (300.64)

582.34 (339.00)

0.816b

Whole brain

1,421.78 (703.77)

1,429.13 (715.83)

1,417.15 (689.60)

0.645b

Thalamus

17.41 (2.54)

17.62 (2.60)

17.27 (2.48)

0.743b

Caudate

9.15 (1.27)

9.14 (1.36)

9.15 (1.21)

0.999b

Putamen

12.00 (2.00)

12.13 (2.14)

11.92 (1.90)

0.33b

Globus pallidus

4.34 (0.83)

4.52 (0.83)

4.22 (0.80)

0.450b

Hippocampus

9.74 (1.48)

9.75 (1.50)

9.73 (1.48)

0.968b

Amygdala

2.35 (0.73)

2.60 (0.76)

2.20 (0.66)

0.034b

Accumbens

1.18 (0.28)

1.17 (0.26)

1.18 (0.29)

0.834b

Corpus callosum

42.91 (5.00)

42.79 (5.12)

42.99 (4.98)

0.865b

  1. All p-values were adjusted for multiple comparisons using the false discovery rate method.
  2. Significant p-values are shown in bold.
  3. RRMS relapsing–remitting multiple sclerosis, CSF cerebrospinal fluid, OCB oligoclonal IgG bands, SD standard deviation.
  4. The difference of the means was calculated using aPearson’s chi-square test or bANCOVA, and adjusted for disease duration.
Back to article page